• Thursday, May 2, 2019 @ 4:30 pm

Swissfillon AG , an agile fill & finish contract manufacturing organization (CMO) for complex pharmaceutical and biopharmaceutical products, today announces successful facility inspection of its GMP manufacturing site, located in Visp, Switzerland.

Swissfillon production site in Visp has been assessed by USFDA – US Food and Drug Administration – between April 15 and 24, 2019. The focus was on the fill & finish process related to a high delicate drug product and turned out in an overall positive evaluation from auditors. Swissfillon has been serving, since few years, the European market with its integrated capabilities to manage highly viscous, complex to fill, oil-based drugs and bubble-free filling solutions for cartridge and syringe-based drug delivery systems. Thanks to this achievement, Swissfillon is now well positioned to address the growing American pharma and biopharmaceutical industry needs.

Daniel Kehl, Swissfillon CEO, commented: “We are extremely proud of such an outstanding result, which is the outcome of the long-term commitment and experience of all our technicians and scientists. We have designed our facility with reduced footprint for efficient and flexible small-scale manufacturing, which is ideal for the current needs of pharma and biopharma customers. This milestone represents a further step in the development plan of our company to provide solutions for a high standard pharmaceutical environment, complying with the most stringent quality requirements.”

You may also be interested in